Analysis of Molecular Networks in the Cerebellum in Chronic Schizophrenia: Modulation by Early Postnatal Life Stressors in Murine Models.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
17 Sep 2021
Historique:
received: 31 05 2021
revised: 08 09 2021
accepted: 09 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 16 11 2021
Statut: epublish

Résumé

Despite the growing importance of the cerebellum as a region highly vulnerable to accumulating molecular errors in schizophrenia, limited information is available regarding altered molecular networks with potential therapeutic targets. To identify altered networks, we conducted one-shot liquid chromatography-tandem mass spectrometry in postmortem cerebellar cortex in schizophrenia and healthy individuals followed by bioinformatic analysis (PXD024937 identifier in ProteomeXchange repository). A total of 108 up-regulated proteins were enriched in stress-related proteins, half of which were also enriched in axonal cytoskeletal organization and vesicle-mediated transport. A total of 142 down-regulated proteins showed an enrichment in proteins involved in mitochondrial disease, most of which were also enriched in energy-related biological functions. Network analysis identified a mixed module of mainly axonal-related pathways for up-regulated proteins with a high number of interactions for stress-related proteins. Energy metabolism and neutrophil degranulation modules were found for down-regulated proteins. Further, two double-hit postnatal stress murine models based on maternal deprivation combined with social isolation or chronic restraint stress were used to investigate the most robust candidates of generated networks. CLASP1 from the axonal module in the model of maternal deprivation was combined with social isolation, while YWHAZ was not altered in either model. METTL7A from the degranulation pathway was reduced in both models and was identified as altered also in previous gene expression studies, while NDUFB9 from the energy network was reduced only in the model of maternal deprivation combined with social isolation. This work provides altered stress- and mitochondrial disease-related proteins involved in energy, immune and axonal networks in the cerebellum in schizophrenia as possible novel targets for therapeutic interventions and suggests that METTL7A is a possible relevant altered stress-related protein in this context.

Identifiants

pubmed: 34576238
pii: ijms221810076
doi: 10.3390/ijms221810076
pmc: PMC8469990
pii:
doi:

Substances chimiques

14-3-3 Proteins 0
CLASP1 protein, human 0
Carrier Proteins 0
Microtubule-Associated Proteins 0
YWHAZ protein, human 0
NADH Dehydrogenase EC 1.6.99.3
NDUFB9 protein, human EC 7.1.1.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS098329
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM119536
Pays : United States
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : SAF2016-75500R
Organisme : NIH HHS
ID : GM 119536 and R01 NS098329
Pays : United States
Organisme : CONICYT-Becas Chile 2015
ID : 72160426
Organisme : Miguel Servet
ID : MS16/00153-CP16/00153

Références

Dev Psychobiol. 2016 Dec;58(8):937-944
pubmed: 27132477
Schizophr Bull. 2009 May;35(3):528-48
pubmed: 19223657
Transl Psychiatry. 2016 Apr 05;6:e772
pubmed: 27045842
Bipolar Disord. 2011 Aug-Sep;13(5-6):474-85
pubmed: 22017217
Nucleic Acids Res. 2002 Jan 1;30(1):163-5
pubmed: 11752281
Biol Psychiatry. 1999 Sep 1;46(5):703-11
pubmed: 10472423
Behav Brain Res. 2001 Nov 29;126(1-2):57-63
pubmed: 11704252
J Neurosci. 2006 Mar 22;26(12):3309-18
pubmed: 16554481
Mol Neuropsychiatry. 2018 Feb;3(3):157-169
pubmed: 29594135
Neurosci Biobehav Rev. 2015 Apr;51:151-63
pubmed: 25616179
Behav Brain Res. 2017 Jul 28;331:30-37
pubmed: 28527693
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
Sci Rep. 2017 Jul 7;7(1):4850
pubmed: 28687733
Mol Psychiatry. 2013 Dec;18(12):1308-14
pubmed: 23147385
Eur Neuropsychopharmacol. 2011 Mar;21(3):254-60
pubmed: 21123035
Biomed Res Int. 2014;2014:414351
pubmed: 24772423
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Neuropsychopharmacology. 1996 Mar;14(3 Suppl):1S-11S
pubmed: 8866738
Front Cell Neurosci. 2019 Jan 29;13:5
pubmed: 30787869
Mol Psychiatry. 2007 Jan;12(1):74-86
pubmed: 17043677
Proteomics. 2015 Aug;15(15):2597-601
pubmed: 25921073
Exp Ther Med. 2018 Dec;16(6):4519-4526
pubmed: 30542400
Eur Psychiatry. 2011 Jan;26(1):45-56
pubmed: 20980130
Eur Arch Psychiatry Clin Neurosci. 2021 Sep;271(6):1089-1109
pubmed: 32926285
Mol Psychiatry. 2021 Mar;26(3):784-799
pubmed: 31142819
Epidemiol Rev. 2008;30:67-76
pubmed: 18480098
Mol Psychiatry. 2018 Feb;23(2):295-303
pubmed: 27801890
Schizophr Bull. 2001;27(3):457-76
pubmed: 11596847
Mol Psychiatry. 2004 Jul;9(7):684-97, 643
pubmed: 15098003
Genome Med. 2017 Jul 28;9(1):72
pubmed: 28754123
Neurosci Lett. 2002 Jan 14;317(3):161-5
pubmed: 11755264
Schizophr Res. 2017 Sep;187:17-25
pubmed: 28189530
BMC Genomics. 2012;13 Suppl 8:S20
pubmed: 23282288
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):601-12
pubmed: 26232077
Nat Rev Immunol. 2016 May 27;16(6):378-91
pubmed: 27231052
PLoS One. 2020 Jul 8;15(7):e0230400
pubmed: 32639965
Schizophr Bull. 2017 Mar 1;43(2):459-471
pubmed: 27451428
Psychiatr Genet. 2010 Aug;20(4):166-70
pubmed: 20421850
Mol Psychiatry. 2004 Jan;9(1):14-27
pubmed: 14581932
Front Pharmacol. 2017 Dec 13;8:910
pubmed: 29321741
Neuroscience. 2013 Sep 26;249:172-91
pubmed: 23298853
Med Hypotheses. 2010 Mar;74(3):555-63
pubmed: 19836903
BMC Psychiatry. 2009 Apr 30;9:17
pubmed: 19405953
Neuron. 2000 Oct;28(1):53-67
pubmed: 11086983
Front Neuroendocrinol. 2019 Jul;54:100774
pubmed: 31348932
Schizophr Res. 2016 Oct;176(2-3):83-94
pubmed: 27450778
Eur J Neurosci. 2003 Mar;17(6):1296-302
pubmed: 12670318
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5861-6
pubmed: 21422296
Int J Neuropsychopharmacol. 2012 Oct;15(9):1229-39
pubmed: 22152146
Synapse. 2009 Sep;63(9):794-804
pubmed: 19489049
Metab Brain Dis. 2016 Feb;31(1):121-33
pubmed: 26555398
J Cereb Blood Flow Metab. 2012 Jul;32(7):1222-32
pubmed: 22434069
Arch Gen Psychiatry. 1988 Nov;45(11):1055
pubmed: 3178414
Neurosci Biobehav Rev. 2015 Jan;48:10-21
pubmed: 25446950
Cogn Neuropsychiatry. 2021 May;26(3):166-182
pubmed: 33706673
Biol Psychiatry. 2018 Mar 15;83(6):492-498
pubmed: 28987712
Neurosci Biobehav Rev. 2016 Jun;65:185-94
pubmed: 27073049
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6917-22
pubmed: 11381111
Schizophr Res. 2001 Mar 1;48(1):125-36
pubmed: 11278159
BMC Genomics. 2007 Nov 12;8:413
pubmed: 17997842
Antioxid Redox Signal. 2011 Oct 1;15(7):2067-79
pubmed: 20673161
J Psychiatr Res. 2010 Dec;44(16):1176-89
pubmed: 20471030
PLoS One. 2012;7(3):e34053
pubmed: 22479520
Curr Opin Cell Biol. 2013 Aug;25(4):483-8
pubmed: 23510681
Biol Psychiatry. 2011 Jan 15;69(2):163-72
pubmed: 20887976
Psychol Med. 2021 Apr;51(6):1038-1048
pubmed: 31941558
Mol Psychiatry. 2015 Apr;20(4):424-32
pubmed: 25048004
Front Neurosci. 2017 Sep 07;11:493
pubmed: 28936160
J Hum Evol. 2000 Feb;38(2):317-32
pubmed: 10656781
J Comp Neurol. 1972 Aug;145(4):399-463
pubmed: 5044254
Psychosom Med. 2020 Jul/Aug;82(6):623-630
pubmed: 32310840
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
BMC Cancer. 2017 Feb 20;17(1):145
pubmed: 28219369
Nature. 2011 May 12;473(7346):221-5
pubmed: 21490598
Behav Brain Res. 2004 Jul 9;152(2):279-95
pubmed: 15196796
J Proteomics. 2020 Jul 15;223:103814
pubmed: 32389842
Cereb Cortex. 2002 Apr;12(4):349-56
pubmed: 11884350
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11032-7
pubmed: 11005874
Cerebellum. 2014 Feb;13(1):151-77
pubmed: 23996631

Auteurs

América Vera-Montecinos (A)

Psiquiatria Molecular, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, 08950 Esplugues de Llobregat, Spain.

Ricard Rodríguez-Mias (R)

Department of Genome Sciences, School of Medicine, University of Washington, 3720 15th Ave NE, Seattle, WA 98195, USA.

Karina S MacDowell (KS)

Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Instituto Universitario de Investigación en Neuroquímica IUIN-UCM, Avda. Complutense s/n, 28040 Madrid, Spain.
Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM (Biomedical Network Research Center of Mental Health), Institute of Health Carlos III, 28029 Madrid, Spain.

Borja García-Bueno (B)

Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Instituto Universitario de Investigación en Neuroquímica IUIN-UCM, Avda. Complutense s/n, 28040 Madrid, Spain.
Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM (Biomedical Network Research Center of Mental Health), Institute of Health Carlos III, 28029 Madrid, Spain.

Álvaro G Bris (ÁG)

Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Instituto Universitario de Investigación en Neuroquímica IUIN-UCM, Avda. Complutense s/n, 28040 Madrid, Spain.
Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM (Biomedical Network Research Center of Mental Health), Institute of Health Carlos III, 28029 Madrid, Spain.

Javier R Caso (JR)

Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Instituto Universitario de Investigación en Neuroquímica IUIN-UCM, Avda. Complutense s/n, 28040 Madrid, Spain.
Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM (Biomedical Network Research Center of Mental Health), Institute of Health Carlos III, 28029 Madrid, Spain.

Judit Villén (J)

Department of Genome Sciences, School of Medicine, University of Washington, 3720 15th Ave NE, Seattle, WA 98195, USA.

Belén Ramos (B)

Psiquiatria Molecular, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, 08950 Esplugues de Llobregat, Spain.
Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM (Biomedical Network Research Center of Mental Health), Institute of Health Carlos III, 28029 Madrid, Spain.
Parc Sanitari Sant Joan de Déu, Doctor Antoni Pujadas 42, 08830 Sant Boi de Llobregat, Spain.
Faculty of Medicine, University of Vic-Central University of Catalonia, 08500 Vic, Spain.
Departamento de Bioquímica i Biología Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH